WallStreetZenWallStreetZen

NASDAQ: MXCT
Maxcyte Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their MXCT stock forecasts and price targets.

Forecast return on equity

Is MXCT forecast to generate an efficient return?

Company
-6.64%
Industry
27.4%
Market
211.34%
MXCT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is MXCT forecast to generate an efficient return on assets?

Company
-5.61%
Industry
14.81%
MXCT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

MXCT earnings per share forecast

What is MXCT's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$0.28
Avg 2 year Forecast
-$0.22
Avg 3 year Forecast
-$0.20

MXCT revenue forecast

What is MXCT's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$40.1M+16.64%
Avg 2 year Forecast
$50.0M+45.38%
Avg 3 year Forecast
$69.8M+102.82%
MXCT's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MXCT revenue growth forecast

How is MXCT forecast to perform vs Medical Devices companies and vs the US market?

Company
24.76%
Industry
9.63%
Market
23.08%
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MXCT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MXCT vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
MXCT$0.91N/AN/A
ARAY$0.81$4.00+395.66%Strong Buy
OM$5.01$14.00+179.44%Strong Buy
HYPR$1.12$1.43+27.23%Buy
SRTS$5.13$7.00+36.45%Strong Buy
View Top Medical Device Stocks

Maxcyte Stock Forecast FAQ

What is MXCT's earnings growth forecast for 2026-2028?

(NASDAQ: MXCT) Maxcyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 18.21%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.88%.

Maxcyte's earnings in 2026 is -$45,631,000.On average, 9 Wall Street analysts forecast MXCT's earnings for 2026 to be -$29,740,714, with the lowest MXCT earnings forecast at -$47,043,239, and the highest MXCT earnings forecast at -$22,401,542. On average, 6 Wall Street analysts forecast MXCT's earnings for 2027 to be -$23,212,265, with the lowest MXCT earnings forecast at -$28,225,943, and the highest MXCT earnings forecast at -$14,561,003.

In 2028, MXCT is forecast to generate -$21,761,498 in earnings, with the lowest earnings forecast at -$20,908,106 and the highest earnings forecast at -$22,401,542.

If you're new to stock investing, here's how to buy Maxcyte stock.

What is MXCT's revenue growth forecast for 2026-2028?

(NASDAQ: MXCT) Maxcyte's forecast annual revenue growth rate of 24.76% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.63%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.08%.

Maxcyte's revenue in 2026 is $34,419,000.On average, 9 Wall Street analysts forecast MXCT's revenue for 2026 to be $4,282,748,194, with the lowest MXCT revenue forecast at $3,920,269,904, and the highest MXCT revenue forecast at $4,805,130,825. On average, 6 Wall Street analysts forecast MXCT's revenue for 2027 to be $5,337,967,510, with the lowest MXCT revenue forecast at $4,599,783,354, and the highest MXCT revenue forecast at $5,745,995,603.

In 2028, MXCT is forecast to generate $7,446,806,034 in revenue, with the lowest revenue forecast at $7,154,732,592 and the highest revenue forecast at $7,665,807,778.

What is MXCT's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: MXCT) forecast ROA is -5.61%, which is lower than the forecast US Medical Devices industry average of 14.81%.

What is MXCT's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: MXCT) Maxcyte's current Earnings Per Share (EPS) is -$0.44. On average, analysts forecast that MXCT's EPS will be -$0.28 for 2026, with the lowest EPS forecast at -$0.44, and the highest EPS forecast at -$0.21. On average, analysts forecast that MXCT's EPS will be -$0.22 for 2027, with the lowest EPS forecast at -$0.26, and the highest EPS forecast at -$0.14. In 2028, MXCT's EPS is forecast to hit -$0.20 (min: -$0.20, max: -$0.21).

What is MXCT's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: MXCT) forecast ROE is -6.64%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.